Just how prevalent is pharmacogenomic information on European drug labels?
Stephanie Sutton |
Advances in DNA sequencing, and a thirst for biostatistics and bioinformatics… the era of genetics is truly upon us – and increasingly found on our drug labels, with a growing number incorporating pharmacogenomic information (1). According to a group of regulatory experts who recently reviewed the labels of all 517 medicinally products centrally approved in the EU until August 2014, the next challenge is to assess how such information will be used to improve drug therapy and patient outcomes.
“Almost 15 percent of medicine labels examined contained pharmacogenomic information that directly impacts patient treatment. One of the aims of our study was to address how prevalent pharmacogenomics labeling is in Europe at the moment,” says Falk Ehmann, lead author of the study and scientific secretariat of the European Medicines Agency’s (EMA) Pharmacogenomics Working Party.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.